Will Chemist Warehouse’s UK Expansion Plans Pay Off? Here’s What Pexa and Nick Scali’s Experiences Can Tell Us!

Sigma Healthcare’s (ASX: SIG) announcement this week that Chemist Warehouse will enter the United Kingdom via a joint venture with London-based Greenlight Healthcare is the latest in a growing line of ASX companies betting that Britain offers the next great growth chapter.

The question investors should be asking is whether that bet is well-placed — and what the experiences of predecessors like PEXA (ASX: PXA) and Nick Scali (ASX: NCK) reveal about the UK as an expansion destination compared to Asia or the United States.

The UK as a Market: Familiar, But Not Easy

On paper, the UK holds obvious appeal for Australian companies. A shared language, common law heritage, broadly comparable consumer preferences and a population of 68 million make it the path of least cultural resistance for any ASX business looking offshore. The UK is also one of the world’s largest consumer markets, with retail spending of approximately £440bn per year, and a pharmacy sector worth roughly £30bn annually, making it a logical destination for a business of Chemist Warehouse’s scale.

The economic backdrop, however, is more complicated. The UK has endured persistent inflationary pressure, with core inflation remaining stubbornly above the Bank of England’s 2% target through much of 2024 and 2025. Consumer confidence has been fragile, household disposable income squeezed by elevated mortgage costs, and discretionary spending under pressure. The post-Brexit regulatory environment has added operational complexity for businesses dependent on European supply chains, while labour costs have risen meaningfully following successive increases to the National Living Wage.

The regulatory environment for pharmacy specifically warrants attention. UK pharmacy is substantially more tightly governed than Australia’s. The NHS underpins the dispensary function, meaning that private-label and front-of-shop retail — which is where Chemist Warehouse’s margin engine operates — must coexist alongside government-contracted dispensary economics. Community pharmacies in the UK have also faced significant funding pressure from NHS England, with hundreds of independent pharmacies closing over the past decade. That context complicates any assumption that an Australian discount pharmacy model translates directly.

Against Asia or the US, the UK has some advantages and clear limitations. Southeast Asian markets offer faster demographic growth and a rising middle class but present far more acute regulatory, cultural and supply chain complexity. The US holds enormous scale potential but is, as Chemist Warehouse founder Jack Gance has himself acknowledged, encumbered by its pharmacy benefit manager (PBM) system, which structurally disadvantages new retail entrants. On balance, the UK sits in a sensible middle ground: manageable regulatory complexity, meaningful market size, and a consumer base predisposed to value-oriented retail formats — provided the market conditions cooperate.

PEXA: A Cautionary Tale of Regulatory Dependency

PEXA’s UK experience is instructive, and not in an encouraging way. The company entered the UK market after acquiring Smoove, a cloud-based conveyancing platform, as the vehicle for its property settlement ambitions. The logic was coherent: replicate Australia’s successful e-conveyancing monopoly in a UK market still heavily reliant on paper-based processes.

The problem is that PEXA’s Australian success was, in important respects, a product of compulsion rather than pure market appeal. State governments mandated the shift to electronic conveyancing, and the country’s major banks were co-owners with an incentive to drive adoption. Neither condition exists in the UK. Without a governing mandate forcing conveyancers and lenders onto the platform, PEXA has had to sell its value proposition into a market that sees operational risk in switching, not reward. Conveyancers, notably, stand to lose the deposit interest they earn during the settlement window — a structural disincentive PEXA has struggled to overcome.

The company’s FY25 results confirmed the difficulty. Group revenue rose 16% to $393.6m and Australian operating cash flow reached $138.7m, but the international division continued to generate losses, contributing to a statutory net loss of $76.1m. Management acknowledged that material UK revenue remains 18 to 24 months away.

The market’s verdict has been blunt: analysts at Morningstar assigned only a 25% probability of successful UK market entry and attributed roughly $1.75 per share of value to the UK business, at a time when the share price had largely ceased attributing any. PEXA’s UK expansion has been slower, costlier and harder to articulate commercially than management initially indicated. The lesson is clear — regulatory tailwinds that make a business dominant at home do not travel.

Nick Scali: Work in Progress, But a More Credible Blueprint

Nick Scali’s UK venture tells a more nuanced story. The company acquired Fabb Furniture’s 21-store network in 2024 when that business was distressed, obtaining UK retail property at discount prices and pairing an established store footprint with Nick Scali’s vertically integrated supply chain and buying power. The strategy mirrors its successful 2021 acquisition of Plush, where management lifted gross margins from 54.8% to 62.7% through product range transition and procurement leverage.

The early numbers from the UK are painful but arguably expected. Nick Scali’s FY25 statutory profit fell 28.3% to $57.7m, with UK losses of $11.2m for the full year as the company absorbed store refurbishment costs and cleared legacy Fabb inventory. UK gross margins at acquisition were 41% — well below the 65% Nick Scali generates in ANZ.

By the first quarter of FY26, those margins had risen to 58.3%, and the four like-for-like Nick Scali branded UK stores posted 32% written sales order growth in January 2026. Management has identified a break-even revenue position of approximately $53m once all 20 stores trade under the Nick Scali brand. Ord Minnett expects the UK business to reach profitability by FY28.

Whether that timeline proves accurate is the open question. The UK consumer remains under pressure, and Nick Scali’s premium-to-accessible furniture positioning in Britain faces a crowded competitive landscape with IKEA, DFS and a range of established mid-market players. Written orders for August and September 2025 reached $7.6m across 13 to 14 stores — an encouraging signal, but still a long way from $53m annualised. That said, management’s track record with turnaround acquisitions warrants some benefit of the doubt, and the balance sheet remains healthy, with $91.7m in cash as of December 2025.

Sigma’s UK Bet: Structured for Risk Management

Against this backdrop, Sigma’s entry structure looks relatively sensible. Rather than acquiring an existing UK pharmacy business outright, the company has formed a joint venture with Greenlight Healthcare, acquiring a 75% stake in an initial tranche of stores and licensing the Chemist Warehouse brand and intellectual property to the venture. Greenlight retains responsibility for dispensary operations and back-office support — the parts of the UK pharmacy space most exposed to NHS regulatory complexity.

Phase one covers up to five stores, with expansion contingent on their performance. The first site is planned to be on Hoxton Street in northeast London. Sigma’s approximate share of capex for the initial UK phase is not large in the context of the group’s overall investment profile, with A$40m earmarked for NZ distribution centre automation alone. The company can therefore absorb a measured UK failure without existential balance sheet consequences. UBS described the entry as “judicious,” pointing to the disciplined use of a local partner and the limited initial commitment.

The broader backdrop for Sigma is supportive. The existing international store network, covering New Zealand, Ireland and Dubai, grew total sales 24.7% and like-for-like sales 11.8% for the nine months to March 2026. The Ireland presence is arguably the most relevant analogue — a common law English-speaking market with NHS-adjacent pharmacy regulation — and it has performed well. The Chemist Warehouse model’s fundamental appeal, which is high-volume, discount-led pharmacy retail with a recognisable brand and aggressive promotional marketing, has shown it can travel.

Verdict: UK Is Workable, But Won’t Be a Shortcut

In our view, the UK is neither the obvious nor the inferior choice for Sigma/Chemist Warehouse nor for any other ASX companies seeking offshore growth. It offers scale, cultural proximity and regulatory manageability relative to Asia or the US.

But it does not reward companies that assume their domestic competitive advantages will transplant automatically. PEXA discovered that without regulatory compulsion, network-effect businesses must earn adoption the hard way. Nick Scali is learning that margin improvement is achievable but slow, and that UK consumer sentiment can be unforgiving during the transition.

We think Sigma’s UK ambitions look more likely to succeed than PEXA’s because they are anchored in physical retail and brand differentiation rather than regulatory dependency, and because management has structured the entry to limit downside. Whether Chemist Warehouse can ultimately replicate its disruptive pricing model in a market shaped by NHS funding dynamics and established pharmacy chains remains an open question.

But Sigma’s phased, partnership-driven approach suggests management understands the risks, and is building in the room to learn from them.